Orchestra BioMed Holdings Inc’s recent filing unveils that its 10% Owner PERCEPTIVE ADVISORS LLC acquired Company’s shares for reported $1.93 million on Aug 01 ’25. In the deal valued at $2.75 per share,700,000 shares were bought. As a result of this transaction, PERCEPTIVE ADVISORS LLC now holds 5,292,556 shares worth roughly $14.34 million.
Then, Hochman David P bought 20,000 shares, generating $55,000 in total proceeds. Upon buying the shares at $2.75, the insider now owns 349,331 shares.
Before that, Fain Eric S sold 2,683 shares. Orchestra BioMed Holdings Inc shares valued at $8,183 were divested by the Director at a price of $3.05 per share. As a result of the transaction, Fain Eric S now holds 50,949 shares, worth roughly $0.14 million.
BTIG Research initiated its Orchestra BioMed Holdings Inc [OBIO] rating to a Buy in a research note published on March 20, 2025; the price target was $12. A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in early January with a ‘”an Overweight”‘ rating. H.C. Wainwright began covering OBIO with “Buy” recommendation on August 22, 2024. B. Riley Securities started covering the stock on July 25, 2024. It rated OBIO as “a Buy”.
Price Performance Review of OBIO
On Friday, Orchestra BioMed Holdings Inc [NASDAQ:OBIO] saw its stock jump 4.23% to $2.71. Over the last five days, the stock has gained 11.07%. Orchestra BioMed Holdings Inc shares have fallen nearly -57.59% since the year began. Nevertheless, the stocks have fallen -32.25% over the past one year.
How much short interest is there in Orchestra BioMed Holdings Inc?
A steep rise in short interest was recorded in Orchestra BioMed Holdings Inc stocks on 2025-07-15, dropping by -0.5 million shares to a total of 0.56 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 1.06 million shares. There was a decline of -90.21%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 19, 2024 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $14 price target.
